KTN's online platform helps you to make the connections you need

 

The Knowledge Transfer Network (KTN) has refreshed its online platform to intelligently connect you to relevant events, funding, thought pieces and specialist staff to help your business innovate and grow.

You can discover content using your area of interest, from Defence Security to transport; from space to health – all major UK economic sectors are covered. Once you have selected your interests, using our intelligent tagging system, we will then display rich and relevant content related to your area, often from surprising sources.

An example might be new satellite technology from the space sector that is applicable in the agri-food sector. KTN-UK.co.uk will help you form these unusual and valuable connections.

All content on the platform has been carefully curated by our team of innovation specialists – not by an automated algorithm – so you can be confident that KTN is connecting you to the most relevant cutting-edge information.

 

The move also marks a closer alignment with our main funder, Innovate UK , with the website branding making a clear visual link. Knowledge Transfer Network is Innovate UK's innovation network partner, and also works with other funders to provide innovation networking services and fulfil our mission to drive UK growth.

We link new ideas and opportunities with expertise, markets and finance through our network of businesses, universities, funders and investors. From agri-food to autonomous systems and from energy to design, KTN combines expertise in all sectors with the ability to cross boundaries. Connecting with KTN can lead to potential partners, horizon-expanding events and innovation insights relevant to your needs.

Visit our people pages to connect directly with expertise in your sector.

Visit the KTN refreshed online platfom here

Entries with tag therapy .

The Cell And Gene Therapy Catapult and University of Aberdeen Launch Islexa to Develop Novel Diabetes Technology

The Cell and Gene Therapy Catapult (CGT) and University of Aberdeen, UK, announce the creation of Islexa, a new company developing a novel technology to produce laboratory grown islets, the organoids responsible for insulin production.  The technology could bring the option of an islet transplant to thousands more patients with type I diabetes. Currently in the UK, only 30-50...
Read More About The Cell And Gene Therapy Catapult and University of Aberdeen Launch Islexa to Develop Novel Diabetes Technology »

Funding Opportunities for SMEs in the Healthcare Sector: Webinar

    Funding Opportunities for SMEs in the Healthcare Sector - Webinar T he Cell and Gene Therapy Catapult, the Knowledge Transfer Network and H2020 National Contact Points will deliver a webinar on 30 June 2016 to highlight the forthcoming opportunities in Horizon 2020 Healthcare...
Read More About Funding Opportunities for SMEs in the Healthcare Sector: Webinar »

New Collaboration Opportunities In Regenerative Medicine

New Collaboration Opportunities in Regenerative Medicine and Addressing Challenges to Clinical Adoption of Cell and Gene Therapies New Hunts House Guy’s campus King’s College London London SE1 1UL 14 th June 2016 The KTN in collaboration with Innovate UK, Cell and Gene Therapy Catapult, Department of Health and Kings College London are holding an event...
Read More About New Collaboration Opportunities In Regenerative Medicine »

Oxford Biomedica updates on LentiVector

Oxford BioMedica plc, a leading gene and cell therapy company, today announces that new data has been presented from two clinical studies indicating ground-breaking long-term four-year sustained and, in one of the studies, dose-dependent gene expression with the Company’s LentiVector® delivery platform. On 5 May 2016, Professor Stéphane Palfi presented a poster on OXB-101, a gene...
Read More About Oxford Biomedica updates on LentiVector »

New gene therapy for the treatment of children with ultra-rare immune disorder recommended for approval

GlaxoSmithKline has received a thumbs-up from a European Medicines Agency committee for its groundbreaking new gene therapy treatment--but it's already thinking about pricing as it gears up for a final European approval in the coming months. The CHMP--the safety and efficacy arm of the European regulator--recommended approval of GSK's new drug Strimvelis on Friday to treat the incredibly...
Read More About New gene therapy for the treatment of children with ultra-rare immune disorder recommended for approval »

Minister joins ReNeuron Board on tour of their new premises

Economy Minister Edwina Hart joined the ReNeuron Board this week on a tour of their new premises at the Welsh Government’s state-of-the-art Advanced Therapy Medical Productions manufacturing facility at Pencoed. ReNeuron plc, the leading clinical stage stem cell business, has now relocated its operations from Guilford, in a move that was supported by the Wales Life Science Investment...
Read More About Minister joins ReNeuron Board on tour of their new premises »

New Approaches to Diagnosis and Therapy in Dementia

Life Science Leadership Series: New Approaches to Diagnosis and Therapy in Dementia on 22 March in Windlesham.  This event will gather a mix of academic and industry speakers to discuss current and new approaches to diagnosis, drug development and therapy in Dementia. It is aimed to anybody with an interest in Dementia whether they have technologies that could apply to the area or...
Read More About New Approaches to Diagnosis and Therapy in Dementia »

ReNeuron wins major UK grant to advance its exosome nanomedicine platform

ReNeuron Group plc, a leading UK-based stem cell therapy development company, announce that it has been awarded a £2.1 million grant from Innovate UK to further advance its emerging exosome nanomedicine platform. Read more here  
Read More About ReNeuron wins major UK grant to advance its exosome nanomedicine platform »

Synpromics and Cell Therapy Catapult collaborate to develop viral vector manufacturing platform

Synpromics Ltd, a leading synthetic biology company, and The Cell Therapy Catapult, the UK organisation accelerating the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, announce the launch of a collaboration to remove a major barrier to the development of the cell and gene therapy industry by reducing the cost and...
Read More About Synpromics and Cell Therapy Catapult collaborate to develop viral vector manufacturing platform »

Cell and Gene Therapy Manufacturing: Getting it right from the start

This three day training course is offered by the  Cell Therapy Catapult ,  UCL Biochemical Engineering  and the  amc . It is designed for cell and gene therapy professionals, from both industry and academia, who need to understand the manufacturing challenges and are planning, or progressing, a therapy through the R&D translation phases and into routine clinical...
Read More About Cell and Gene Therapy Manufacturing: Getting it right from the start »

Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the release of their 2015 Annual Review. The link to the annual review can be found here:  https://ct.catapult.org.uk/annual-review The second review covers the 12 months from...
Read More About Cell Therapy Catapult details key milestones and achievements in 2015 Annual Review »

Cell Therapy Catapult signs major development agreement with Asterias Biotherapeutics Inc

The Cell Therapy Catapult, the UK organisation dedicated to the growth of the UK cell and gene therapy industry by bridging the gap between scientific research and commercialisation, today announces the signing of an agreement with Asterias Biotherapeutics Inc (NYSE MKT: AST). The agreement engages the Cell Therapy Catapult to advance development of a large scale manufacturing processes for...
Read More About Cell Therapy Catapult signs major development agreement with Asterias Biotherapeutics Inc »

UK Cell Therapy GMP Manufacturing Capacity and Capability Increases

The Cell Therapy Catapult has published its annual survey of the GMP licensed cell and gene manufacturing capability and capacity in the UK, which shows growth in the cell therapy industry to April 2015. Key findings include: 25% increase in the numbers of highly-skilled staff at cell therapy facilities Addition of 2 cell therapy manufacturing centres 16% growth in the...
Read More About UK Cell Therapy GMP Manufacturing Capacity and Capability Increases »

Workshop on the Cryopreservation of Cell Therapies

Thursday 11th June 2015, Glasgow Workshop on the Cryopreservation of Cell Therapies Cryopreservation is a bottleneck in the clinical delivery of cell based therapies (CBT) which allows efficiencies of scale in manufacturing, reduces cost of goods, facilitates quality control, and enable multi-centre trials with optimal timing of delivery to patients. However, the application of...
Read More About Workshop on the Cryopreservation of Cell Therapies »

Cell Therapy Catapult to create cutting-edge global manufacturing site in Stevenage

The Cell Therapy Catapult, which is focused on the development of the UK cell therapy industry to increase the nation's health and wealth, has chosen to build its £55m state-of-the-art Cell Therapy manufacturing centre in Stevenage, UK. Its position on the Stevenage Bioscience Catalyst campus will provide additional inward investment from global companies, as well support the SME biotech...
Read More About Cell Therapy Catapult to create cutting-edge global manufacturing site in Stevenage »

Request for EOI: Challenge Call from Cell Therapy Catapult - Thaw in Clinic Technology

The Cell Therapy Catapult (CTC) is providing an opportunity for experienced and qualified suppliers to participate in a challenge call for Thaw in Clinic Technology.    This collaboration with a suitable partner will develop Thaw in Clinic Technology which will both fill a crucial gap in the GMP logistics chain and enable CTC to develop capabilities in device engineering...
Read More About Request for EOI: Challenge Call from Cell Therapy Catapult - Thaw in Clinic Technology »

London Regenerative Medicine Network : Open Invitation

London Regenerative Medicine Network invite you to thier December 2014 meeting. The meeting will be focused on cell therapy commercialisation, and three experts with differing experiences from academic and commercial settings will be presenting their thoughts and experiences in getting to market.   This meeting is the third meeting supported by the Cell Therapy Catapult and...
Read More About London Regenerative Medicine Network : Open Invitation »
Showing 17 results.
Items per Page 25
of 1